Utilizing an antagonistic peptide, FIP-1, which comprises a FOXM1-targeting peptide and a cell-penetrating peptide sequence with FoxM1 inhibitory properties, the researchers linked FIP-1 with the E3 ubiquitin ligase ligand pomalidomide to form FoxM1-PROTAC, demonstrating a stronger inhibitory effect on cancer cells than FIP-1 alone.513. Here, FOXM1 is linked to cancer.